Nevirapine and cardiovascular risk;Névirapine et risque cardiovasculaire

Medecine et Maladies Infectieuses

Volumn 40, Issue 9, 2010, Pages 499-505

  Parienti, J J ^a   Verdon, R ^a  

^a CHU CÔTE DE NACRE   (France)

Author keywords

Antiretroviral drugs; Cardiovascular risk; Lipid metabolism; Nevirapine

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; APOLIPOPROTEIN A1; ATAZANAVIR; EFAVIRENZ; EMTRICITABINE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INDINAVIR; LAMIVUDINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NEVIRAPINE; RITONAVIR; TENOFOVIR; TRIACYLGLYCEROL; ZIDOVUDINE;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DRUG EXPOSURE; DYSLIPIDEMIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; LIPOGENESIS; MEDICAL DECISION MAKING; MORBIDITY; REVIEW; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME;

ANTI-HIV AGENTS; CARDIOVASCULAR DISEASES; HUMANS; NEVIRAPINE; RISK FACTORS;

EID: 77957754756     PISSN: 0399077X     EISSN: 17696690     Source Type: Journal    
DOI: 10.1016/j.medmal.2010.02.002     Document Type: Review

References (50)

1. Grunfeld C., Kotler D.P., Hamadeh R., Tierney A., Wang J., et al. Hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J Med 1989, 86:27-31.
2. Grunfeld C., Pang M., Doerrler W., Shigenaga J.K., Jensen P., et al. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 1992, 74:1045-1052.
3. Riddler S.A., Smit E., Cole S.R., Li R., Chmiel J.S., et al. Impact of HIV infection and HAART on serum lipids in men. JAMA 2003, 289:2978-2982.
4. Palella F.J., Delaney K.M., Moorman A.C., Loveless M.O., Fuhrer J., et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV outpatient study investigators. N Engl J Med 1998, 338:853-860.
5. Friis-Moller N., Sabin C.A., Weber R., d'Arminio Monforte A., El-Sadr W.M., et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003, 349:1993-2003.
6. Carr A., Samaras K., Thorisdottir A., Kaufmann G.R., Chisholm D.J., et al. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999, 353:2093-2099.
7. Karmochkine M., Raguin G. Severe coronary artery disease in a young HIV-infected man with no cardiovascular risk factor who was treated with indinavir. AIDS 1998, 12:2499.
8. Henry K., Melroe H., Huebsch J., Hermundson J., Levine C., et al. Severe premature coronary artery disease with protease inhibitors. Lancet 1998, 351:1328.
9. Maggi P., Serio G., Epifani G., Fiorentino G., Saracino A., et al. Premature lesions of the carotid vessels in HIV-1-infected patients treated with protease inhibitors. AIDS 2000, 14:F123-F128.
10. Holmberg S.D., Moorman A.C., Williamson J.M., Tong T.C., Ward D.J., et al. Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet 2002, 360:1747-1748.
11. Mary-Krause M., Cotte L., Simon A., Partisani M., Costagliola D. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS 2003, 17:2479-2486.
12. Phillips AN, Carr A, Neuhaus J Interruption of ART and risk of cardiovascular disease: findings from SMART. 14th Conference on retroviruses and opportunistic infection (CROI), Los Angeles, February 25-28;2007, Abstract 41.
13. Fontas E., van Leth F., Sabin C.A., Friis-Moller N., Rickenbach M., et al. Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles?. J Infect Dis 2004, 189:1056-1074.
14. van der Valk M., Kastelein J.J., Murphy R.L., van Leth F., Katlama C., et al. Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an antiatherogenic lipid profile. AIDS 2001, 15:2407-2414.
15. Clotet B., van der Valk M., Negredo E., Reiss P. Impact of nevirapine on lipid metabolism. J Acquir Immune Defic Syndr 2003, 34(Suppl 1):S79-S84.
16. Soriano V, Koeppe S, Mingrone H, et al. Prospective comparison of nevirapine and atazanavir/ritonavir both combined with tenofovir DF/emtricitabine in treatment-naïve HIV-1 infected patients: ARTEN study week 48 results. 5th International AIDS Society Conference on HIV pathogenesis, treatment, and prevention (IAS). Cape Town, South Africa. July 19-22, 2009 (Abstract LBPEB07).
17. Martinez E., Arnaiz J.A., Podzamczer D., Dalmau D., Ribera E., et al. Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection. N Engl J Med 2003, 349:1036-1046.
18. Mocroft A, Lacombe K, Rockstroh J, Gasiorowski J, Antunes F, et al. Risk of discontinuation of nevirapine due to toxcities in antiretroviral naive and experienced patients with high and low CD4 counts. XVI IAC Toronto, Aug 2006.
19. Kesselring A.M., Wit F.W., Sabin C.A., Lundgren J.D., Gill M.J., et al. Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapy. AIDS 2009, 23:1689-1699.
20. van Leth F., Phanuphak P., Ruxrungtham K., Baraldi E., Miller S., et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet 2004, 363:1253-1263.
21. van Leth F., Phanuphak P., Stroes E., Gazzard B., Cahn P., et al. Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1. PLoS Med 2004, 1:e19.
22. van Leth F., Hall D.B., Lange J.M., Reiss P. Plasma lipid concentrations after 1.5 years of exposure to nevirapine or efavirenz together with stavudine and lamivudine. HIV Med 2006, 7:347-350.
23. Mobius U., Lubach-Ruitman M., Castro-Frenzel B., Stoll M., Esser S., et al. Switching to atazanavir improves metabolic disorders in antiretroviral-experienced patients with severe hyperlipidemia. J Acquir Immune Defic Syndr 2005, 39:174-180.
24. Tashima K.T., Bausserman L., Alt E.N., Aznar E., Flanigan T.P. Lipid changes in patients initiating efavirenz- and indinavir-based antiretroviral regimens. HIV Clin Trials 2003, 4:29-36.
25. Saag M.S., Powderly W.G., Schambelan M. Switching antiretroviral drugs for treatment of metabolic complications in HIV-1 infection: summary of selected trials. Topics HIV Med 2002, 10:47-51.
26. Martinez E., Conget I., Lozano L., Casamitjana R., Gatell J.M. Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine. AIDS 1999, 13:805-810.
27. Negredo E., Cruz L., Paredes R., Ruiz L., Fumaz C.R., et al. Virological, immunological, and clinical impact of switching from protease inhibitors to nevirapine or to efavirenz in patients with human immunodeficiency virus infection and longlasting viral suppression. Clin Infect Dis 2002, 34:504-510.
28. Fisac C., Fumero E., Crespo M., Roson B., Ferrer E., et al. Metabolic benefits 24 months after replacing a protease inhibitor with abacavir, efavirenz or nevirapine. AIDS 2005, 19:917-925.
29. Negredo E., Ribalta J., Paredes R., Ferre R., Sirera G., et al. Reversal of atherogenic lipoprotein profile in HIV-1 infected patients with lipodystrophy after replacing protease inhibitors by nevirapine. AIDS 2002, 16:1383-1389.
30. Parienti J.J., Massari V., Rey D., Poubeau P., Verdon R. Efavirenz to nevirapine switch in HIV-1-infected patients with dyslipidemia: a randomized, controlled study. Clin Infect Dis 2007, 45:263-266.
31. Ward D.J., Curtin J.M. Switch from efavirenz to nevirapine associated with resolution of efavirenz-related neuropsychiatric adverse events and improvement in lipid profiles. AIDS Patient Care STDS 2006, 20:542-548.
32. Calza L., Manfredi R., Colangeli V., Tampellini L., Sebastiani T., et al. Substitution of nevirapine or efavirenz for protease inhibitor versus lipid-lowering therapy for the management of dyslipidaemia. AIDS 2005, 19:1051-1058.
33. Manfredi R., Calza L., Chiodo F. An extremely different dysmetabolic profile between the two available non-nucleoside reverse transcriptase inhibitors: efavirenz and nevirapine. J Acquir Immune Defic Syndr 2005, 38:236-238.
34. Young J., Weber R., Rickenbach M., Furrer H., Bernasconi E., et al. Lipid profiles for antiretroviral-naive patients starting PI- and NNRTI-based therapy in the Swiss HIV cohort study. Antivir Ther 2005, 10:585-591.
35. Sankatsing R.R., Wit F.W., Vogel M., de Groot E., Brinkman K., et al. Increased carotid intima-media thickness in HIV patients treated with protease inhibitors as compared to nonnucleoside reverse transcriptase inhibitors. Atherosclerosis 2009, 202:589-595.
36. Domingo P., Matias-Guiu X., Pujol R.M., Domingo J.C., Arroyo J.A., et al. Switching to nevirapine decreases insulin levels but does not improve subcutaneous adipocyte apoptosis in patients with highly active antiretroviral therapy-associated lipodystrophy. J Infect Dis 2001, 184:1197-1201.
37. Franssen R., Sankatsing R.R., Hassink E., Hutten B., Ackermans M.T., et al. Nevirapine increases high-density lipoprotein cholesterol concentration by stimulation of apolipoprotein A-I production. Arterioscler Thromb Vasc Biol 2009, 29:1336-1341.
38. Sankatsing R.R., Wit F.W., Pakker N., Vyankandondera J., Mmiro F., et al. Effects of nevirapine, compared with lamivudine, on lipids and lipoproteins in HIV-1-uninfected newborns: the stopping infection from mother-to-child via breast-feeding in Africa lipid substudy. J Infect Dis 2007, 196:15-22.
39. Virgili N., Fisac C., Martinez E., Ribera E., Gatell J.M., et al. Pro-inflammatory cytokine changes in clinically stable, virologically suppressed, HIV-infected patients switching from protease inhibitors to abacavir. J Acquir Immune Defic Syndr 2009, 50:552-553.
40. Petit J.M., Duong M., Masson D., Buisson M., Duvillard L., et al. Serum adiponectin and metabolic parameters in HIV-1-infected patients after substitution of nevirapine for protease inhibitors. Eur J Clin Invest 2004, 34:569-575.
41. Redhage L.A., Shintani A., Haas D.W., Emeagwali N., Markovic M., et al. Clinical factors associated with plasma F2-isoprostane levels in HIV-infected adults. HIV Clin Trials 2009, 10:181-192.
42. Hulgan T., Morrow J., D'Aquila R.T., Raffanti S., Morgan M., et al. Oxidant stress is increased during treatment of human immunodeficiency virus infection. Clin Infect Dis 2003, 37:1711-1717.
43. Friis-Moller N., Reiss P., Sabin C.A., Weber R., Monforte A., et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007, 356:1723-1735.
44. El-Sadr W.M., Lundgren J.D., Neaton J.D., Gordin F., Abrams D., et al. CD4+ countguided interruption of antiretroviral treatment. N Engl J Med 2006, 355:2283-2296.
45. Heeschen C., Hamm C.W., Laufs U., Snapinn S., Bohm M., et al. Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation 2002, 105:1446-1452.
46. Barreiro P., Soriano V., Blanco F., Casimiro C., de la Cruz J.J., et al. Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy. AIDS 2000, 14:807-812.
47. Ruiz L., Negredo E., Domingo P., Paredes R., Francia E., et al. Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with HIV-associated lipodystrophy: 1-year prospective follow-up of a multicenter, randomized, controlled study. J Acquir Immune Defic Syndr 2001, 27:229-236.
48. Raffi F., Bonnet B., Ferre V., Esnault J.L., Perre P., et al. Substitution of a nonnucleoside reverse transcriptase inhibitor for a protease inhibitor in the treatment of patients with undetectable plasma human immunodeficiency virus type 1 RNA. Clin Infect Dis 2000, 31:1274-1278.
49. Negredo E., Ribalta J., Ferre R., Salazar J., Rey-Joly C., et al. Efavirenz induces a striking and generalized increase of HDL-cholesterol in HIV-infected patients. AIDS 2004, 18:819-821.
50. Buisson M, Grappin M, Piroth L, Duong M, Portier H, et al. Simplified maintenance therapy with NNRTI (nevirapine) in patients with long-term suppression of HIVRNA: first results of a cohort study. 40th Interscience Conference on antimicrobial agent and chemotherapy September17-20, 2000, Toronto, Canada (Abstract 1541).